Prostaglandin Receptor

Receptor

Prostaglandin Receptor

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Isoform Comparison

Prostaglandin Receptor Related Products (607)
Antibodies (2)
Prostaglandin Receptor Isoform Comparison

By Effects:	Controls (50) Inhibitors (118) Ligand (1) Agonists (154) Degrader (1) Antagonists (132) Activators (24) Modulators (2) Inducer (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-101952

Prostaglandin E2	Activator	99.76%
Prostaglandin E2 (PGE2) is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.

HY-101840

EIPA	Inhibitor	99.73%
EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA also enhances autophagy by inhibiting Na⁺/H⁺-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.

HY-B0131

Prostaglandin E1	Agonist	99.76%
Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with K_is of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases.

HY-108566

U-46619	Agonist	≥99.0%
U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation.

HY-101988

Prostaglandin D2	Activator	99.5%
Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. Prostaglandin D2 is one of the most potent endogenous sleep promoting substances. PGD2 plays a protective role by suppressing inflammation.

HY-B0813R

Treprostinil (diethanolamine) (Standard)	Agonist
Geniposide (Standard) is the analytical standard of Geniposide. This product is intended for research and analytical applications. Geniposide is an iridoid glucoside extracted from Gardenia jasminoidesEllis fruits; exhibits a varity of biological activities such as anti-diabetic, antioxidative, antiproliferative and neuroprotective activities.

HY-159704

9-Keto-latanoprost	Control
9-keto latanoprost is a derivative of the F-prostaglandin (FP) receptor agonist Latanoprost (HY-B0577).

HY-137585

17-Trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α	Control
17-Trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α is a derivative of Bimatoprost acid (HY-125774).

HY-12956

Dinoprost	Agonist	99.63%
Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost plays a key role in the onset and progression of labour.

HY-B0195

Tranilast	Inhibitor	99.58%
Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC₅₀= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells.

HY-18966

PF-04418948	Antagonist	99.40%
PF-04418948 is an orally active, potent and selective prostaglandin EP₂ receptor antagonist with an IC₅₀ of 16 nM.

HY-50901

ONO-AE3-208	Antagonist	98.65%
ONO-AE3-208 is a selective and orally active EP4 receptor antagonist with a K_i of 1.3 nM. ONO-AE3-208 shows less potently affects EP3, FP, and TP receptors (K_i of 30 nM, 790 nM, and 2400 nM, respectively). ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.

HY-101840A

EIPA hydrochloride	Inhibitor	98.31%
EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC₅₀ of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na⁺/H⁺-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.

HY-B0577

Latanoprost	Agonist	99.85%
Latanoprost (PHXA41) is a prostaglandin F2α analogue and can be used for glaucoma research. Latanoprost can effectively pass through cornea and be hydrolyzed by esterase to latanoprost acid. latanoprost acid is an F-prostaglandin (FP) receptor agonist, and can effectively reduce intraocular pressure (IOP) by increasing the outflow of aqueous humor through uvea.

HY-100441

Treprostinil	Inhibitor	99.98%
Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC₅₀ values of 0.6±0.1 and 6.2±1.2 nM, respectively.

HY-14870

Selexipag	Agonist	99.86%
Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI₂) receptor (IP receptor).

HY-103088

Palupiprant	Antagonist	99.60%
Palupiprant (E7046) is an orally bioavailable and specific EP4 antagonist, with IC₅₀ of 13.5 nM and K_i of 23.14 nM. Palupiprant exhibits anti-tumor activities.

HY-A0096

Iloprost	Agonist	99.76%
Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research.

HY-10835

DG-041	Antagonist	99.61%
DG-041 is a potent, high affinity and selective EP₃ receptor antagonist with IC₅₀s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier.

HY-106420

16,16-Dimethyl prostaglandin E2	Modulator	≥99.0%
16,16-Dimethyl prostaglandin E2 (16,16-dimethyl PGE2) is an orally active vertebrate Hematopoietic stem cells (HSCs) homeostasis critical regulator. 16,16-Dimethyl prostaglandin E2 can act through EP2/EP4 and has an interaction with the Wnt pathway.

Prostaglandin E2		EP					99.76%
Prostaglandin E1		EP					99.76%
U-46619					TXA₂/TP		≥99.0%
Prostaglandin D2	DP						99.5%
Dinoprost			FP Receptor				99.63%
Tranilast	DP2, IC₅₀: 0.1 mM						99.58%
PF-04418948		EP2, IC₅₀: 16 nM					99.40%
ONO-AE3-208		EP4, Ki: 1.3 nM EP3, Ki: 30 nM	FP, Ki: 790 nM		TP Receptor, Ki: 2400 nM		98.65%
Latanoprost			FP Receptor				99.85%
Treprostinil			FP Receptor, Ki: 4680 nM	IP Receptor, EC₅₀: 1.9 nM IP Receptor, Ki: 32.1 nM	TP Receptor, EC₅₀: 919 nM		99.98%
Selexipag				hIP, Ki: 260 nM			99.86%
Iloprost				IP			99.76%
DG-041		EP3, IC₅₀: 4.6-8.1 nM					99.61%
16,16-Dimethyl prostaglandin E2		EP2 EP4					≥99.0%
L-798106		EP3, IC₅₀: 0.3 nM EP4, IC₅₀: 916 nM EP1, IC₅₀: >5000 nM EP2, IC₅₀: >5000 nM					99.91%
L-161982		EP4					99.04%
Laropiprant	DP, Ki: 0.57 nM				TP Receptor, Ki: 2.95 nM		99.93%
RO1138452				Rat I₂ Receptor, IC₅₀: 7 nM Rat I₂ Receptor, pKi: 8.33			≥98.0%
Grapiprant		dog EP4, IC₅₀: 35 nM dog EP4, Ki: 24 nM					99.57%
GW627368		EP					99.81%
Asapiprant	DP1, Ki: 0.44 nM						99.53%
Ginsenoside Ro					TXA₂		99.81%
Travoprost			FP				99.99%
Ramatroban	hDP2, IC₅₀: 113 nM hDP2, IC₅₀: 33.4 μM				hTP, IC₅₀: 14 nM		99.10%
Omidenepag		hEP4, IC₅₀: 5480 nM hEP2, IC₅₀: 10 nM hEP2, EC₅₀: 1.1 nM					99.86%
Prostaglandin E2-d₄		EP					99.90%
L-902688		EP4, Ki: 0.38 nM EP4, EC₅₀: 0.6 nM					≥99.0%
Cefminox sodium				IP Receptor			99.83%
Seratrodast					TXA₂/TP		98.86%
Pectolinarin		EP					99.89%
p-Hydroxycinnamic acid						TXB₂, IC₅₀: 371 μM	99.94%
Nedocromil	PGD2						98.75%
NTP42					TXA₂		98.58%
Beraprost sodium				IP			99.88%
MRE-269				IP Receptor			99.91%
Ebopiprant			Human FP Receptor, Ki: 1 nM Rat FP Receptor, Ki: 26 nM				98.65%
Fevipiprant	DP2, Kd: 1.14 nM						99.38%
AZD1981	DP						99.37%
Omidenepag isopropyl		EP2					99.20%
TG4-155		EP2, Ki: 9.9 nM					99.91%
Prostaglandin E2 (Standard)		EP
Prostaglandin J2	hDP, Ki: 0.9 nM hCRTH2, Ki: 6.6 nM	hEP1, Ki: 15.678 μM hEP2, Ki: 989 nM hEP3, Ki: 319 nM hEP4, Ki: 1065 nM	hFP, Ki: 553 nM	hIP, Ki: >25 μM	hTP, Ki: 6426 nM		98.10%
Timapiprant	DP						99.48%
CJ-42794		EP, EC₅₀: 10 nM					98.96%
Treprostinil sodium	DP1, EC₅₀: 0.6±0.1 nM DP1, Ki: 4.4 nM	EP2, EC₅₀: 6.2±1.2 nM EP2, Ki: 3.6 nM EP4, Ki: 826 nM EP3, Ki: 2505 nM EP1, Ki: 212 nM EP1, EC₅₀: 285 nM EP3, EC₅₀: 68.9 nM EP4, EC₅₀: 181 nM	FP Receptor, Ki: 4680 nM	IP Receptor, EC₅₀: 1.9 nM IP Receptor, Ki: 32.1 nM	TP Receptor, EC₅₀: 919 nM		99.78%
BW 245C	DP						99.73%
Ozagrel					TXA₂		99.74%
MF498		EP4, Ki: 0.7 nM					99.26%
SC-51322		EP2, pA2: 8.1					98.90%
L 888607	DP, Ki: 0.8 nM		FP Receptor, Ki: 10018 nM	IP Receptor, Ki: 14434 nM	TP Receptor, Ki: 283 nM		99.87%
Ridogrel		EP					99.64%
Carbacyclin				PGI₂ Receptor			98.00%
EP2 receptor antagonist-2		EP					98.69%
Latanoprost acid			FP				99.62%
Evatanepag		EP2					99.78%
MF-766		EP4, Ki: 0.23 nM					99.69%
Licarin A	DP						98.48%
(+)-Cloprostenol			PGF_2α				99.28%
Vorbipiprant		human EP4-R, Ki: 16.6 nM					99.72%
CAY10471 Racemate	CRTH2, Ki: 0.6 nM						99.00%
Dinoprost tromethamine salt			FP Receptor				≥98.0%
EP3 antagonist 3		EP3, pKi: 8.3					99.52%
Setipiprant	hCRTH2, IC₅₀: 6 nM hDP1, IC₅₀: 1290 nM	EP2, IC₅₀: 2600 nM					98.23%
Sulprostone		EP3					≥99.0%
Epibetulinic acid		EP2, IC₅₀: 0.6 μM					≥98.0%
PDC31			FP Receptor, Ki: ~30 nM				99.76%
Ozagrel hydrochloride					TXA₂/TP		99.68%
Misoprostol acid		EP					≥99.0%
SC 51089 free base		EP1, Ki: 1.3 μM EP3, Ki: 17.5 μM	FP, Ki: 61.1 μM		TP, Ki: 11.2 μM		98.64%
EP2 receptor antagonist-1		EP2					99.45%
EP4 receptor agonist 2		EP4, EC₅₀: 0.8 nM EP2, Ki: >100000 nM EP3, Ki: 38000 nM EP4, Ki: 3.1 nM					≥99.0%
Ralinepag	hDP1, EC₅₀: 850 nM			hIP, EC₅₀: 8.5 nM rIP, EC₅₀: 530 nM			99.79%
L-826266		EP3					≥98.0%
BI-671800	hCRTH2, IC₅₀: 4.5 nM mCRTH2, IC₅₀: 3.7 μM						99.36%
Taprenepag isopropyl		EP2					99.23%
BAY-6672 hydrochloride			FP				98.44%
BAY 73-1449				IP Receptor, IC₅₀: <0.1 nM			99.99%
Ozagrel sodium					TXA₂		99.98%
MK-7246	DP, Ki: 2.5 nM				TP, Ki: 3804 nM		99.63%
Treprostinil palmitil	DP						99.62%
SC-19220		EP					99.71%
Picotamide					TXA₂/TP		99.76%
BW A868C	DP2						99.00%
AAT-008		EP4, Ki: 0.97 nM EP4, IC₅₀: 6.1 nM					98.55%
CAY10580		EP4, Ki: 35 nM EP2, Ki: 3000 nM EP3, Ki: 2000 nM EP1, Ki: >3000 nM
Darbufelone mesylate			PGF_2α				99.65%
Pexopiprant	DP2, Ki: <100 nM						99.40%
PROTAC(H-PGDS)-7	DP						99.42%
EP4-IN-1		EP4					99.94%
15-keto-Prostaglandin F2a			FP				99.2%
AMG-009	DP, IC₅₀: 12 nM CRTH2, IC₅₀: 3 nM						98.08%
Carboprost tromethamine			FP				99.85%
PGN-9856		EP2, pEC₅₀: ≥ 8.5 EP2, pKi: ≥ 8.3					98.90%
Pizuglanstat	DP						99.70%
BAY-1316957		human EP4-R, IC₅₀: 15.3 nM					99.73%
Aganepag isopropyl		EP					98.61%
Nedocromil sodium	DP
KW-8232		EP					98.10%
Tafluprost acid		EP3, IC₅₀: 67 nM	Human FP Receptor, Ki: 0.4 nM Human FP Receptor, EC₅₀: 0.53 nM				99.80%
Daltroban					TXA₂		98.1%
Carboprost			FP				99.83%
Tiaprost			PGF_2α				≥98.0%
KP496					TXA₂ Receptor		99.79%
BGC-20-1531 free base		EP4, pKd: 7.6					98.05%
KW-8232 free base		EP
Aganepag		EP2, EC₅₀: 0.19 nM					99.71%
Treprostinil diethanolamine	DP1, Ki: 4.4 nM	EP2, Ki: 3.6 nM EP1, Ki: 212 nM EP4, Ki: 826 nM EP3, Ki: 2505 nM	FP, Ki: 4680 nM	IP, Ki: 32.1 nM			99.44%
Taprostene				IP
17-Phenyl-ω-trinor-PGE2		EP1 EP3					≥98.0%
L 888607 Racemate	DP1, Ki: 132 nM				TP, Ki: 17 nM		99.81%
Prostaglandin D2-d₉	DP						≥99.0%
Selexipag-d₇				IP			98.44%
Rivenprost		EP4, Ki: 0.7 nM					≥99.0%
CAY10471	CRTH2
SC 51089		EP1, Ki: 1.3 μM EP3, Ki: 17.5 μM	FP, Ki: 61.1 μM		TP, Ki: 11.2 μM
GSK-269984A		EP1, pIC₅₀: 7.9					99.74%
ONO-8711		EP
Tranilast sodium	DP2, IC₅₀: 0.1 mM
Iloprost-d₄				IP
Sulotroban					TXA₂ Receptor
EP4 receptor antagonist 2		EP4, IC₅₀: 7.8 nM
Ifetroban					TXA₂/TP		99.65%
Cicaprost				IP
BAY-6672			FP
Laropiprant sodium	DP, Ki: 0.57 nM				TP, Ki: 2.95 nM
MK-8318	DP, Ki: 5.0 nM
GSK345931A		EP1
Prostaglandin E1-d₉		EP
(R)-Vorbipiprant		hEP4, Ki: 16.6 nM
Selexipag-d₆				IP
L-644698	hDP receptor, Ki: 0.9 nM	hEP2, Ki: 267 nM hEP3, Ki: 3730 nM hEP4, Ki: 9280 nM
MK-447				PGI₂
ASP7657 free base		hEP4, IC₅₀: 2.21 nM rat EP4, IC₅₀: 6.02 nM
Nocloprost		EP1 EP3
Travoprost (Standard)			FP
I-SAP					TXA₂ Receptor
2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide				PGI₂
Treprostinil-¹³C₂,d	DP	EP
Prostaglandin E2-d₉		EP
Prostaglandin E1 (Standard)		EP
EP4 receptor agonist 1		hEP4, pEC₅₀: 6.3
Cloprostenol isopropyl ester			FP
Misoprostol acid-d₅		EP
TP-16		EP4, IC₅₀: 2.1 nM
AGN 210676	hDP receptor, EC₅₀: 7749 nM	EP2, EC₅₀: 5 nM hEP3, EC₅₀: 153 nM
CAY10535			FP Receptor		TP Receptor
Prostaglandin F2α dimethyl amine			FP
AMX12006		hEP4, IC₅₀: 4.3 nM
TG6-129		EP
Prostaglandin D2-d₄	DP
Saikogenin D		EP					99.99%
CAY10595	DP, Ki: 10 nM
Ramatroban-d₄					TXA₂/TP
Latanoprost (Standard)			FP Receptor
EP3 antagonist 6		EP3, IC₅₀: 1.9 nM
ICI 192605					TXA₂/TP
Etersalate					TXA₂
Terbogrel					TXA₂/TP
BM567					TXA₂ Receptor, IC₅₀: 1.1 nM TXA₂ synthase, IC₅₀: 12 nM
8-iso-15-keto Prostaglandin F2α			FP
11-Deoxy-16,16-dimethyl-PGE2		EP2 EP3
ER-819762		EP4, IC₅₀: 70 nM
Thromboxane A2					TP
EP2 receptor agonist 4		EP2, EC₅₀: 43 nM
L 657925					TXA₂
Prostaglandin A3		EP2, IC₅₀: 120 nM EP4, IC₅₀: 20 nM
CAY10509			FP, IC₅₀: 30 nM
CRTH2-IN-1	hDP2, IC₅₀: 6 nM hDP1, IC₅₀: 1 μM
LCB-2853					TXA₂ Receptor
AZ-1355				Prostaglandin I₂	TXA₂/TP		98.19%
RS-601					TXA₂ Receptor
CGS 15435					TXA₂, IC₅₀: 1 nM
BGC-20-1531		EP4
CI-949						TXB₂, IC₅₀: 0.1 μM
YM158 free base					TXA₂ Receptor, pA2: 8.81
Bunaprolast						TXB₂
KF 13218						TXB₂, IC₅₀: 5.3 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Related Products (607)

Antibodies (2)

Prostaglandin Receptor Isoform Comparison

Prostaglandin Receptor Related Products (607):